- Poster presentation
- Open Access
Managing non-proportionality of hazards (PH) within TNT: a randomised phase III trial of carboplatin compared to docetaxel for patients with metastatic or recurrent locally advanced triple negative (TN) or brca1/2 breast cancer (BC)
© Tovey et al. 2015
- Published: 16 November 2015
- Breast Cancer
- Breast Cancer
- Breast Cancer Patient
TNT is a trial comparing carboplatin with docetaxel for advanced TN or BRCA1/2 BC patients. TNBC is heterogeneous; median progression-free survival (PFS) is short but some patients have prolonged PFS following treatment. BRCA1/2 patients were hypothesised to respond better to carboplatin. This interaction, with the heterogeneous population, was expected to cause a failure of PH assumptions required for Cox-PH analysis. Therefore, TNT required alternative analysis methods.
376 patients were randomised (1:1) to carboplatin or docetaxel for 6-8 cycles or until progression. Primary endpoint was objective response; PFS was a secondary endpoint. Restricted mean survival (RMS) was used to deal with non-PH. A cut-off of 15months was used. Treatment groups were compared using a t-test. A Cox-PH landmark analysis (LA) splitting data at 3, 6 and 9months and a time-dependent Cox model were also applied.
Kaplan-Meier curves crossed and the PH assumption didn't hold (p=0.02). RMS indicated no difference in PFS between groups; difference=0.4 months (-1.1-0.3); p=0.29. Within each period of the LA, PH assumptions held. Between 0-3months PFS is better for patients on docetaxel (HR=1.73, p=0.001) however for patients with PFS> 6months this reversed (HR=0.63, p=0.05). Beyond 9months there is no significant difference (HR=0.82, p=0.56). A time-dependent Cox model resulted in the same HRs as the LA.
Lack of PH is a common issue in metastatic cancer trials. Often this is ignored and standard Cox regression applied or modelling avoided. TNT has shown that RMS is a suitable alternative for comparing groups in the presence of non-PH.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.